MET

Assets acting on this target.

Class
MET (c-Met)-directed
Pathway
HGF/MET signaling

MET, also called hepatocyte growth factor receptor, is a receptor tyrosine kinase found on the surface of epithelial cells. Its natural ligand, hepatocyte growth factor (HGF), triggers MET dimerization and activation, setting off intracellular signaling that promotes cell growth, survival, motility, and tissue repair. This HGF/MET pathway is important during normal development and wound healing, but in many cancers it becomes abnormally active through gene amplification, activating mutations, protein overexpression, or persistent HGF stimulation from surrounding tissue. Excessive MET signaling drives tumor cell proliferation, invasion, and resistance to other targeted therapies, particularly in lung, gastric, and other epithelial cancers. Because of this, MET has become a therapeutic target across several drug modalities: small-molecule kinase inhibitors that block the enzyme's catalytic activity from inside the cell, monoclonal antibodies that prevent ligand binding or receptor dimerization at the cell surface, and antibody-drug conjugates that use MET binding to deliver cytotoxic payloads selectively into MET-expressing tumor cells. Each approach exploits the same underlying biological rationale (that tumors dependent on aberrant MET signaling can be selectively disrupted) while differing in how directly they interfere with the receptor and in what additional biological effects they produce beyond receptor blockade.

By indication

Related mechanisms

MET drugs compared

13 drugs, stage by indication
13 drugs acting on MET: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
CapmatinibIncyte, Novartissmall moleculeApprovedApproved in Non-Small Cell Lung Cancer
Telisotuzumab VedotinAbbVieantibody-drug conjugateApprovedApproved in Non-Small Cell Lung Cancer
TepotinibTepmetkoMerck KGaAsmall moleculeApprovedApproved in Non-Small Cell Lung Cancer
ASKC202Jiangsu Aosaikang Pharmaceuticalsmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
GlumetinibHaihe Biopharma, Taiho Pharmaceuticalsmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
SavolitinibOrpathysAstraZeneca, HUTCHMEDsmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Renal Cell Carcinoma
Telisotuzumab AdizutecanAbbVieantibody-drug conjugatePhase 3Phase 3 in Advanced Metastatic Colorectal Cancer; Phase 3 in Colorectal Cancer; Phase 3 in Non-Small Cell Lung Cancer
VebreltinibApollomics Inc., Avistone Biotechnologysmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Non-Small Cell Lung Cancer with MET Exon 14 Skipping; Phase 1 in Glioma
RC108RemeGen Co., Ltd.antibody-drug conjugatePhase 2Phase 2 in Non-Small Cell Lung Cancer
CKD-703Chong Kun Dang Pharmaceuticalantibody-drug conjugatePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
DavutamigRegeneron Pharmaceuticalsbispecific antibodyPhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
VERT-002Pierre Fabre Medicamentmonoclonal antibodyPhase 1/2Not recorded
DO-2DeuterOncologysmall moleculePhase 1Phase 1 in Non-Small Cell Lung Cancer

← all mechanisms